{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T06:24:09Z","timestamp":1773037449677,"version":"3.50.1"},"reference-count":15,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Antiviral drugs were rapidly implemented into clinical practice for the treatment of high\u2010risk patients with COVID\u201019, prompting the development of statewide guidelines. This South\u2010Australian study reviewed guideline adherence, assessed prescribing patterns and highlighted the inappropriate management of relative drug\u2013drug interactions and dosing for renal function. Additionally, it evaluated the impact of inappropriate antiviral drug use and suggested methods to improve quality use of medicines.<\/jats:p>","DOI":"10.1111\/imj.16254","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T03:14:22Z","timestamp":1706152462000},"page":"183-186","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prescribing of antivirals for <scp>COVID\u201019<\/scp> in a South Australian local health network according to statewide guidelines"],"prefix":"10.1111","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6025-799X","authenticated-orcid":false,"given":"Hiba","family":"Al Naji","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology Flinders Medical Centre and Flinders University  Adelaide South Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua M.","family":"Inglis","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Flinders Medical Centre and Flinders University  Adelaide South Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Tucker","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit Flinders Medical Centre  Adelaide South Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra","family":"Rowett","sequence":"additional","affiliation":[{"name":"Drug and Therapeutics Information Service, Southern Adelaide Local Health Network  Adelaide South Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Larcombe","sequence":"additional","affiliation":[{"name":"Pharmacy Services, Flinders Medical Centre, SA Pharmacy  Adelaide South Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Medlin","sequence":"additional","affiliation":[{"name":"Pharmacy Services, Flinders Medical Centre, SA Pharmacy  Adelaide South Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arduino A.","family":"Mangoni","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Flinders Medical Centre and Flinders University  Adelaide South Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tilenka","family":"Thynne","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Flinders Medical Centre and Flinders University  Adelaide South Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"key":"e_1_2_3_2_1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.18773\/austprescr.2022.021","article-title":"Oral antivirals for mild\u2010moderate COVID\u201019: a panacea or a logistical and clinical conundrum?","volume":"45","author":"Coombes ID","year":"2022","journal-title":"Aust Prescr"},{"key":"e_1_2_3_3_1","unstructured":"Guidelines AGDoHaACT.TGA provisionally approves two oral COVID\u201019 treatments molnupiravir (LAGEVRIO) and nirmatrelvir + ritonavir (PAXLOVID). In: Administration TG ed. Available from URL:https:\/\/www.tga.gov.au\/news\/media-releases\/tga-provisionally-approves-two-oral-covid-19-treatments-molnupiravir-lagevrio-and-nirmatrelvir-ritonavir-paxlovid2022"},{"key":"e_1_2_3_4_1","unstructured":"2 CIDSM.COVID\u201019: Treatment Recommendations for Hospitalised Adult Patients. In: CALHN Drugs and Therapeutics Committee C\u2010MAG ed. 1 ed2022:37."},{"key":"e_1_2_3_5_1","unstructured":"Liverpool Uo.Covid\u201019 Drug Interactions; 2022. Available from URL:https:\/\/www.covid19-druginteractions.org\/"},{"key":"e_1_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11040468"},{"key":"e_1_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.11.1348"},{"key":"e_1_2_3_8_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2011-000796","article-title":"Understanding variation in primary medical care: a nine\u2010country qualitative study of clinicians' accounts of the non\u2010clinical factors that shape antibiotic prescribing decisions for lower respiratory tract infection","volume":"2","author":"Brookes\u2010Howell L","year":"2012","journal-title":"BMJ Open"},{"key":"e_1_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01577-w"},{"key":"e_1_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-016-0739-y"},{"key":"e_1_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.injury.2014.10.015"},{"key":"e_1_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.4.638-656.2005"},{"key":"e_1_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.4161\/viru.23706"},{"key":"e_1_2_3_14_1","first-page":"129","article-title":"Academic detailing has a positive effect on prescribing and decreasing prescription drug costs: a health plan's perspective","volume":"10","author":"Ndefo UA","year":"2017","journal-title":"Am Health Drug Benefits"},{"key":"e_1_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2021.09.009"},{"key":"e_1_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12405"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.16254","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T03:16:02Z","timestamp":1706152562000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.16254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1111\/imj.16254"],"URL":"https:\/\/doi.org\/10.1111\/imj.16254","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2023-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}